These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. MPTP-induced neurotoxicity and the quest for a preventative therapy for Parkinson's disease. Furtado JC; Mazurek MF Can J Neurol Sci; 1991 Feb; 18(1):77-82. PubMed ID: 2036621 [TBL] [Abstract][Full Text] [Related]
3. Mitochondrial mechanisms of neurotoxicity. Nicklas WJ; Saporito M; Basma A; Geller HM; Heikkila RE Ann N Y Acad Sci; 1992 May; 648():28-36. PubMed ID: 1637057 [No Abstract] [Full Text] [Related]
4. Neurochemical responses to 6-hydroxydopamine and L-dopa therapy: implications for Parkinson's disease. Zigmond MJ; Hastings TG; Abercrombie ED Ann N Y Acad Sci; 1992 May; 648():71-86. PubMed ID: 1637074 [No Abstract] [Full Text] [Related]
5. The goldfish as a drug discovery vehicle for Parkinson's disease and other neurodegenerative disorders. Pollard HB; Adeyemo M; Dhariwal K; Levine M; Caohuy H; Markey S; Markey CJ; Youdim MB Ann N Y Acad Sci; 1993 May; 679():317-20. PubMed ID: 8512193 [No Abstract] [Full Text] [Related]
6. In search of the causes of Parkinson's disease, seasons 1 to 4. Elbaz A Eur J Epidemiol; 2011 Jul; 26(7):505-9. PubMed ID: 21626392 [No Abstract] [Full Text] [Related]
7. Rotenone neurotoxicity: a new window on environmental causes of Parkinson's disease and related brain amyloidoses. Trojanowski JQ Exp Neurol; 2003 Jan; 179(1):6-8. PubMed ID: 12504862 [No Abstract] [Full Text] [Related]
8. Genetic and environmental factors in the pathogenesis of Parkinson's disease. Mizuno Y; Shimoda-Matsubayashi S; Matsumine H; Morikawa N; Hattori N; Kondo T Adv Neurol; 1999; 80():171-9. PubMed ID: 10410718 [No Abstract] [Full Text] [Related]
9. Are human neurodegenerative disorders linked to environmental chemicals with excitotoxic properties? Spencer PS; Ludolph AC; Kisby GE Ann N Y Acad Sci; 1992 May; 648():154-60. PubMed ID: 1322079 [TBL] [Abstract][Full Text] [Related]
10. Neurotoxicity of nicotinamide derivatives: their role in the aetiology of Parkinson's disease. Willets JM; Lunec J; Williams AC; Griffiths HR Biochem Soc Trans; 1993 Aug; 21 ( Pt 3)(3):299S. PubMed ID: 8224447 [No Abstract] [Full Text] [Related]
11. Neurotoxicity and the mechanisms of cell death in Parkinson's disease. Schapira AH Adv Neurol; 1996; 69():161-5. PubMed ID: 8615125 [No Abstract] [Full Text] [Related]
12. Chronic administration of MPTP to marmosets. Albanese A; Altavista MC; Gozzo S; Rossi P; Colosimo C; Bentivoglio AR; Perretta G; Elia M; Monaco V; Macchi G Adv Neurol; 1990; 53():239-44. PubMed ID: 1978517 [No Abstract] [Full Text] [Related]
13. Changes of tyrosine hydroxylase in parkinsonian brains and in the brains of MPTP-treated mice. Nagatsu T Adv Neurol; 1990; 53():207-14. PubMed ID: 1978515 [No Abstract] [Full Text] [Related]
14. Characteristics of dopaminergic neurotoxicity produced by MPTP and methamphetamine. Sonsalla PK; Giovanni A; Sieber BA; Donne KD; Manzino L Ann N Y Acad Sci; 1992 May; 648():229-38. PubMed ID: 1637048 [No Abstract] [Full Text] [Related]
15. Environmental neurotoxic chemicals-induced ubiquitin proteasome system dysfunction in the pathogenesis and progression of Parkinson's disease. Sun F; Kanthasamy A; Anantharam V; Kanthasamy AG Pharmacol Ther; 2007 Jun; 114(3):327-44. PubMed ID: 17521740 [TBL] [Abstract][Full Text] [Related]
17. Comparison of MPTP and amphetamines as dopaminergic neurotoxins. Fuller RW Ann N Y Acad Sci; 1992 May; 648():87-95. PubMed ID: 1637075 [No Abstract] [Full Text] [Related]
18. Features of the dopaminergic neurotoxin MPTP. Kopin IJ Ann N Y Acad Sci; 1992 May; 648():96-104. PubMed ID: 1637076 [No Abstract] [Full Text] [Related]
19. Neurotoxicity of an MPTP analogue, 2'CH3-MPTP, on monoaminergic systems in the mouse brain. Gupta M; Chen XL Ann N Y Acad Sci; 1992 May; 648():283-5. PubMed ID: 1353331 [No Abstract] [Full Text] [Related]